Immunoexpression of angiogenesis and proliferation markers in patients treated with cyclosporin a

dc.contributor.authorAfonso, M. [UNESP]
dc.contributor.authorPerrotti, V.
dc.contributor.authorRapani, M.
dc.contributor.authorIaculli, F.
dc.contributor.authorPiccirilli, M.
dc.contributor.authorOnuma, T.
dc.contributor.authorShibli, J. A.
dc.contributor.authorDe Oliveira Bello, V.
dc.contributor.authorSposto, M. R. [UNESP]
dc.contributor.authorArtese, L.
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionKidney Transplant Unit Base Hospital
dc.date.accessioned2018-12-11T16:55:46Z
dc.date.available2018-12-11T16:55:46Z
dc.date.issued2014-01-01
dc.description.abstractAim. In the present immunohistochemical study, the expression of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 in the gingival tissues of renal transplant patients treated with cyclosporin A was assessed. Gingival overgrowth (GO) frequently occurs in transplant patients receiving immunosuppressive drugs such as cyclosporine and this gingival inflammation might play an important role in the pathogenesis of drug-induced GO. Methods. Twenty-eight human gingival biopsies were taken from healthy patients with chronic periodontitis (N.=14 control group), and from renal transplant recipients treated with cyclosporin A (N.=14 test group). The retrieved specimens were immunohistochemically processed and stained for vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67. Results. The levels of vascular endothelial growth factor, nitric oxide synthase 1 and 3, and Ki-67 were found to be significantly different among groups (P>0.001), with patients treated with cyclosporin A showing higher levels of all the analyzed markers compared to control group. Conclusion. In summary, the data from this pilot study suggests that the investigated factors have a role in the inflammation processes associated to immunosuppressive therapy. However, further studies with a larger sample population need to be conducted for an exhaustive knowledge of the mechanisms leading to GO.en
dc.description.affiliationDepartment of Diagnosis and Oral Surgery, Araraquara Dental School, UNESP, Araraquara, SP
dc.description.affiliationDepartment of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti
dc.description.affiliationDepartment of Periodontology, Dental Research Division, Guarulhos University, Guarulhos, SP
dc.description.affiliationKidney Transplant Unit Base Hospital, Brasilia
dc.description.affiliationUnespDepartment of Diagnosis and Oral Surgery, Araraquara Dental School, UNESP, Araraquara, SP
dc.format.extent59-67
dc.identifier.citationMinerva Stomatologica, v. 63, n. 3, p. 59-67, 2014.
dc.identifier.issn1827-174X
dc.identifier.issn0926-4970
dc.identifier.scopus2-s2.0-84899635739
dc.identifier.urihttp://hdl.handle.net/11449/171541
dc.language.isoeng
dc.relation.ispartofMinerva Stomatologica
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectChronic periodontitis
dc.subjectCyclosporine, adverse effects
dc.subjectImmunohistochemistry
dc.subjectVascular endothelial growth factor a
dc.titleImmunoexpression of angiogenesis and proliferation markers in patients treated with cyclosporin aen
dc.typeArtigo

Arquivos